The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N03 | Antiepileptics | |
| 3 | N03A | Antiepileptics | |
| 4 | N03AX | Other antiepileptics | |
| 5 | N03AX09 | Lamotrigine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 300 mg |
| Active Ingredient | Description | |
|---|---|---|
| Lamotrigine |
Lamotrigine is a use and voltage dependent blocker of voltage gated sodium channels. It inhibits sustained repetitive firing of neurons and inhibits release of glutamate (the neurotransmitter which plays a key role in the generation of epileptic seizures). |
| Title | Information Source | Document Type | |
|---|---|---|---|
| GIROTEC Tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| LAMICTAL Dispersible / Chewable tablet | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC | |
| LAMITOR Tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| LAMOTRIGINE / MYLAN Dispersible tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| LAMOTRIX Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
